Economic evaluations of trastuzumab in HER2-positive metastatic breast cancer: A systematic review and critique

European Journal of Health Economics

Volumn 15, Issue 1, 2014, Pages 93-112

  Parkinson, Bonny ^a   Pearson, Sallie Anne ^b   Viney, Rosalie ^a  

^a UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

Author keywords

Breast neoplasms; Cost utility analysis; Costeffectiveness analysis; Economics; Metastatic; Trastuzumab

Indexed keywords

ANASTROZOLE; ANTHRACYCLINE; CAPECITABINE; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIRUBICIN; LAPATINIB; METHOTREXATE; NAVELBINE; PACLITAXEL; TAMOXIFEN; TRASTUZUMAB;

ALOPECIA; ARTICLE; BACKACHE; BREAST METASTASIS; CHILL; CLINICAL EVALUATION; COMPARATIVE EFFECTIVENESS; CONGESTIVE HEART FAILURE; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; COUGHING; DATA SYNTHESIS; DRUG EFFICACY; DYSPNEA; ECONOMIC EVALUATION; EPISTAXIS; FEBRILE NEUTROPENIA; FEVER; HEADACHE; HOT FLUSH; HUMAN; HYPERTENSION; LEUKOPENIA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHINOPHARYNGITIS; SYSTEMATIC REVIEW; THORAX PAIN; VOMITING;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; NEOPLASM METASTASIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTOR, ERBB-2;

EID: 84898597770     PISSN: 16187598     EISSN: 16187601     Source Type: Journal    
DOI: 10.1007/s10198-013-0459-2     Document Type: Article

References (61)

1. Slamon, D.J., et al.: Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N. Engl. J. Med. 344(11), 783-792 (2001)
2. Plosker, G.L., et al.: Trastuzumab: a review of its use in the management of HER2-positive metastatic and early-stage breast cancer. Drugs 66(4), 449-475 (2006)
3. Department of Health and Ageing, Schedule of Pharmaceutical Benefits, Effective 1 January 2012-29 February 2012. 2012, DoHA: Canberra
4. National Institute for Health and Clinical Excellence, Guidance on the use of trastuzumab for the treatment of advanced breast cancer, Technology Appraisal No. 34. 2002, NICE: London
5. Pharmaceutical Benefits Advisory Committee, Public Summary Document, Trastuzumab, powder for IV infusion, 150 mg, Herceptin. November 2008,Department ofHealth andAgeing: Canberra
6. Department of Health and Ageing. Late stage metastatic breast cancer. 2011 [cited 2011 17 October]; Available from: http://www. medicareaustralia.gov. au/provider/patients/late-breast-cancer.jsp
7. Drummond, M., et al.: Economic Evaluation Using Patient-Level Data, in Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford (2005)
8. Drummond M, Experimental versus observational data in the economic evaluation of pharmaceuticals. Med. Decis. Making 18(2 (Apr-Jun Suppl)): S12-S8 (1998)
9. Ferrusi, I.L., et al.: Looking back at 10 years of trastuzumab therapy: what is the role of HER2 testing? A systematic review of health economic analyses. Per. Med. 6(2), 193-215 (2009)
10. Neyt, M.: Cost considerations for monoclonal antibody-targeted therapy in cancer: focus on trastuzumab. Am. J. Cancer. 5(1), 19-26 (2006)
11. Younis, T., et al.: Is trastuzumab a cost-effective treatment for breast cancer? Expert Rev. Pharmacoecon. Outcomes Res. 8(5), 433-442 (2008)
12. Blank, P.R., et al.: Cost effectiveness of cytotoxic and targeted therapy for metastatic breast cancer: a critical and systematic review. Pharmacoeconomics 28(8), 629-647 (2010)
13. Anderson, R.: Systematic reviews of economic evaluations: utility or futility? Health Econ. 19(3), 350-364 (2010)
14. OECD. OECD.StatExtracts, Table 4. PPPs and exchange rates. 2011 [cited 2011 20 June]; Available from:http://stats.oecd.org/Index.aspx?datasetcode=SNA- TABLE4
15. Australian Institute of Health and Welfare, Health expenditure Australia 2008-09, Health and welfare expenditure series no. 42. Cat. no. HWE 51. 2010, AIHW: Canberra
16. Liverpool Reviews & Implementation Group, Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor positive breast cancer which over-expresses HER2, assessment report for the National Institute for Health and Clinical Excellence (NICE). 2010
17. Elkin, E.B., et al.: HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis. J. Clin. Oncol. 22(5), 854-863 (2004)
18. Lidgren, M., et al.: Cost-effectiveness of HER2 testing and trastuzumab therapy for metastatic breast cancer. Acta Oncol. 47(6), 1018-1028 (2008)
19. Matter-Walstra, K.W., et al.: Trastuzumab beyond progression: a cost-utility analysis. Ann. Oncol. 21(11), 2161-2168 (2010)
20. Norum, J., et al.: A monoclonal antibody against HER-2 (trastuzumab) for metastatic breast cancer: a model-based cost-effectiveness analysis. Ann. Oncol. 16(6), 909-914 (2005)
21. Perez-Ellis C, et al., Cost-Effectiveness Analysis of Trastuzumab (Herceptin) in HER2-Overexpressed Metastatic Breast Cancer. Am. J. Clin. Oncol. 32(5), 492-498 (2009)
22. Poncet, B., et al.: Use of the monoclonal antibody anti-HER2 trastuzumab in the treatment of metastatic breast cancer: a costeffectiveness analysis. Am. J. Clin. Oncol. 31(4), 363-368 (2008)
23. NHS Centre for Reviews and Dissemination, A rapid and systematic review of the clinical effectiveness and cost-effectiveness of trastuzumab for breast cancer, report for the National Institute for Health and Clinical Excellence. 2001
24. Bocci, G., et al.: Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. Ann. Oncol. 16(8), 1243-1252 (2005)
25. Neyt, M.J., et al.: Cost-effectiveness of Herceptin: a standard cost model for breast-cancer treatment in a Belgian university hospital. Int. J. Technol. Assess. Health Care 21(1), 132-137 (2005)
26. Garrison Jr, L.P., et al.: The economic value of innovative treatments over the product life cycle: the case of targeted trastuzumab therapy for breast cancer. Value Health 12(8), 1118-1123 (2009)
27. Pharmaceutical Benefits Advisory Committee, Guidelines for preparing submissions to the Pharmaceutical Benefits Advisory Committee (Version 4.3). December 2008, Australian Government, Department of Health and Ageing.: Canberra
28. National Institute for Health and Clinical Excellence, Guide to the methods of technology appraisal. 2008, NICE: London
29. Marty, M., et al.: Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. J. Clin. Oncol. 23(19), 4265-4274 (2005)
30. Kaufman, B., et al.:Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptorpositive metastatic breast cancer: results from the randomized phase III TAnDEM study. J. Clin. Oncol. 27(33), 5529-5537 (2009)
31. von Minckwitz, G., et al.: Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a german breast group 26/breast international group 03-05 study. J. Clin. Oncol. 27(12), 1999-2006 (2009)
32. American College of Physicians: A primer on before-after studies: evaluating a report of a "Successful" intervention. Eff Clin Pract 5(2), 100-101 (2002)
33. Therapeutic Goods Administration, Australian Public Assessment Report for Trastuzumab, Department of Health and Ageing, Editor. 2011: Canberra
34. Drummond, M., et al.: Critical Assessment of Economic Evaluation, in Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford (2005)
35. Atkins K, Evaluating survival data with patient switching, Discussion Paper, Department of Health and Ageing, Editor. Unpublished: Canberra
36. Chen, T., et al.: Risk of cardiac dysfunction with trastuzumab in breast cancer patients: a meta-analysis. Cancer Treat. Rev. 37(4), 312-320 (2011)
37. Lidgren, M., et al.: Health related quality of life in different states of breast cancer. Qual. Life Res. 16(6), 1073-1081 (2007)
38. Brown, R.E., et al.: Cost-utility model comparing docetaxel and paclitaxel in advanced breast cancer patients. Anticancer Drugs 9(10), 899-907 (1998)
39. Hutton, J., et al.: A new decision model for cost-utility comparisons of chemotherapy in recurrent metastatic breast cancer. PharmacoEconomics 9(Suppl 2), 8-22 (1996)
40. Launois, R., et al.: A cost-utility analysis of second line chemotherapy in metastatic breast cancer: Docetaxel versus Paclitacel versus Vinorelbine. Pharmacoeconomics 10(5), 504-521 (1996)
41. Lloyd, A., et al.: Health state utilities for metastatic breast cancer. Br. J. Cancer 95(6), 683-690 (2006)
42. Dolan P, Output measures and valuation in health, in Economic Evaluation in Health Care, M.a.M. Drummond, A., Editor. 2001, Oxford University Press: Oxford
43. Hillner, B.E., et al.: Efficacy and cost-effectiveness of autologous bone marrow transplantation in metastatic breast cancer. Estimates using decision analysis while awaiting clinical trial results. JAMA 267(15), 2055-2061 (1992)
44. Drummond, M., et al.: Cost-Utility Analysis, in Methods for the Economic Evaluation of Health Care Programmes. Oxford University Press, Oxford (2005)
45. Pearson, S.A., et al.: Trastuzumab and metastatic breast cancer: trastuzumab use in Australia-monitoring the effect of an expensive medicine access program. J. Clin. Oncol. 25(24), 3688-3693 (2007)
46. Slamon, D.J., et al.: Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244(4905), 707-712 (1989)
47. Lu CY, et al., Positive Spillover Effects of Prescribing Requirements: Increased Cardiac Testing in Patients Treated with Trastuzumab for HER2? Metastatic Breast Cancer. Intern. Med. J. 42(11), 1229-1235 (2012)
48. Harris, A.H., et al.: The role of value for money in public insurance coverage decisions for drugs in Australia: a retrospective analysis 1994-2004. Med. Decis. Making 28(5), 713-722 (2008)
49. Department of Health and Ageing, Public Summary Document, Trastuzumab, powder for IV infusion, 150 mg, Herceptin. November 2008
50. McKeage KaL-W, K.A.: Trastuzumab: a pharmacoeconomic review of its use in early breast cancer. Pharmacoeconomics 26(8), 699-719 (2008)
51. Extra, J., et al.: Trastuzumab (Herceptin) plus docetaxel versus docetaxel alone as first line treatment of HER2-positive metastatic breast cancer (MBC): results of a randomised multicentre trial. Eur. J. Cancer 2(Suppl), 125 (2004)
52. Gori, S., et al.: Phase II study of weekly paclitaxel and trastuzumab in anthracycline- and taxane-pretreated patients with HER2-overexpressing metastatic breast cancer. Br. J. Cancer 90(1), 36-40 (2004)
53. Colleoni, M., et al.: Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels. Ann. Oncol. 13(1), 73-80 (2002)
54. Cobleigh, M.A., et al.: Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J. Clin. Oncol. 17(9), 2639-2648 (1999)
55. Marty M, et al., Pooled analysis of six trials of trastuzumab (Herceptin): exploratory analysis of changes in left ventricular ejection fraction (LVEF) as a surrogate in clinical cardiac event. Breast Cancer Res. Treat. 2003. 82(Suppl 1): 48 (Abstr 218)
56. Earle, C.C., et al.: Systematic overview of cost-utility assessments in oncology. J. Clin. Oncol. 18(18), 3302-3317 (2000)
57. Johnston, S., et al.: Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J. Clin. Oncol. 27(33), 5538-5546 (2009)
58. Oxford Outcomes, Utility measurement study for patients with metastatic breast cancer treated with tyverb. 2009
59. Doyle, S., et al.: Health state utility scores in advanced non-small cell lung cancer. Lung Cancer 62(3), 374-380 (2009)
60. Cooper, N., et al.: A Bayesian approach to Markov modelling in cost-effectiveness analyses: application to taxane use in advanced breast cancer. J. R. Stat. Soc. 166(3), 389-405 (2003)
61. Le, Q., et al.: Cost-effectiveness analysis of lapatinib in HER-2- positive advanced breast cancer. Cancer 115, 489-498 (2009)